NCT03988036 (Keyriched-1) is a Phase 2 clinical trial of Pembrolizumab in Breast Cancer, sponsored by West German Study Group.

Who is sponsoring NCT03988036?

NCT03988036 is sponsored by West German Study Group.

What drugs are being tested in NCT03988036?

Interventions in NCT03988036: Pembrolizumab, Trastuzumab Biosimilar ABP 980, Pertuzumab.

What condition does NCT03988036 study?

NCT03988036 studies Breast Cancer.

Is NCT03988036 still recruiting?

NCT03988036 is currently completed. Last updated 15 May 2023.

Last reviewed 2023-05-15 · How we verify

NCT03988036: Keyriched-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Completed Phase 2 Last updated 15 May 2023

What this trial tests

Phase 2 trial testing Pembrolizumab in Breast Cancer in 46 participants. Completed in 31 May 2022.

Timeline

18 August 2020

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	West German Study Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	18 August 2020
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	12 locations across Germany

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →
Trastuzumab Biosimilar ABP 980 — full drug profile →
Pertuzumab (pertuzumab) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

West German Study Group — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Keyriched-1 is a multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
Current and future immunotherapy for breast cancer.
Heater NK, Warrior S, Lu J. · · 2024 · cited 38× · PMID 39722028 · DOI 10.1186/s13045-024-01649-z
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.
Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, et al · · 2022 · cited 37× · PMID 35565264 · DOI 10.3390/cancers14092136
Immunotherapy for HER-2 positive breast cancer.
Yang T, Kang L, Li D, Song Y. · · 2023 · cited 15× · PMID 37007133 · DOI 10.3389/fonc.2023.1097983
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila E, Ignatiadis M. · · 2020 · cited 15× · PMID 33574892 · DOI 10.3332/ecancer.2020.1147
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, et al · · 2023 · cited 11× · PMID 36441798 · DOI 10.1158/1078-0432.ccr-22-1587
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives.
Valenza C, Rizzo G, Passalacqua MI, Boldrini L, et al · · 2023 · cited 10× · PMID 36743524 · DOI 10.1177/17588359221146129
Novel HER-2 Targeted Therapies in Breast Cancer.
Fernandes CL, Silva DJ, Mesquita A. · · 2023 · cited 9× · PMID 38201515 · DOI 10.3390/cancers16010087

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other West German Study Group trials

Trials by the same sponsor.

NCT07242352 — Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinica · Phase 3 · not yet recruiting
NCT07178730 — NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple- · Phase 3 · not yet recruiting
NCT04055493 — Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC · Phase 3 · active not recruiting
NCT02269813 — PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative B · completed
NCT01891357 — Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03988036 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West German Study Group
Last refreshed: 15 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing